TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?

This publication has 11 references indexed in Scilit:

• Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards
  Health Economics, Policy and Law, 2008
• Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines
  New England Journal of Medicine, 2007
• Report of the Commission on Intellectual Property Rights: an industry perspective
  Published by WHO Press ,2006
• Estimating The Cost Of New Drug Development: Is It Really $802 Million?
  Health Affairs, 2006
• Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
  2004
• Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
  The Medical Journal of Australia, 2004
• The price of innovation: new estimates of drug development costs
  Journal of Health Economics, 2003
• The pharmaceutical industry as a medicines provider
  The Lancet, 2002
• Pharmaceutical pricing in the developing world: issues of access to medicines
  Expert Review of Pharmacoeconomics & Outcomes Research, 2002
• Aiding the poorest. The Philippines: Children and Youth Foundation.
  1998